Solid Biosciences Inc (SLDB) Stock Analysis
Verdict: WATCH (do not buy)
Binary clinical risk and aggressive cash burn ($156M OCF loss) outweigh recent momentum; the model sees a late-cycle hype trap.
Investment score: 44/100
Analysis as of
Is Solid Biosciences Inc stock worth reviewing? AI model thesis
Pre-revenue biotech with high burn rate and looming dilution risk despite strong technical momentum.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 40/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Solid Biosciences Inc opportunities and risks
What speaks for SLDB
- SGT-003 Clinical Efficacy
What speaks against SLDB
- Capital Exhaustion and Dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SLDB | n/a | 0.0x | n/a | 0.0% | 0.0% | -21.3% |
| CGEM | n/a | 0.0x | n/a | 0.0% | 0.0% | -16.0% |
| ORIC | n/a | 0.0x | n/a | 0.0% | 0.0% | -10.0% |
| DRUG.CN | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.5% |
| SANA | n/a | 0.0x | n/a | 0.0% | 0.0% | -12.7% |
| OLMA | n/a | 0.0x | n/a | 0.0% | 0.0% | -14.4% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -12.7% |
Frequently asked questions about Solid Biosciences Inc (SLDB)
Is SLDB stock a good investment?
The cached TradeMates AI model rates Solid Biosciences Inc as WATCH (do not buy) with an investment score of 44/100. Pre-revenue biotech with high burn rate and looming dilution risk despite strong technical momentum. This is algorithmic model output, not personal investment advice.
Is SLDB stock a buy?
The TradeMates model verdict for SLDB is WATCH (do not buy) with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.